

Stanford



Neel K. Gupta

- Clinical Assistant Professor, Medicine - Oncology
- Clinical Assistant Professor, Medicine - Hematology

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm 2203

MC 6560

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 725-8222

Bio

BIO

Dr. Gupta specializes in the treatment of patients with lymphoma in general, and has particular clinical and research interests in patients with primary central nervous system and immunodeficiency-related lymphomas.

CLINICAL FOCUS

- Cancer > Lymphoma
- Primary Central Nervous System Lymphomas
- Post-transplant Lymphoproliferative Disorders
- AIDS-Related Lymphomas
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology
- Clinical Assistant Professor, Medicine - Hematology

HONORS AND AWARDS

- Saul Rosenberg Faculty Teaching Award, Division of Oncology, Department of Medicine (2020)
- Saul Rosenberg Faculty Teaching Award, Division of Oncology, Department of Medicine (2018)

PROFESSIONAL EDUCATION

- Fellowship: UCSF Hematology and Medical Oncology Fellowship (2013) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2013)
- Residency: University of Washington Medical Center Dept of Medicine (2010) WA
- Medical Education: University of California Davis School of Medicine (2006) CA
- Fellowship: Memorial Sloan-Kettering Cancer Center (2009) NY

- Board Certification: Hematology, American Board of Internal Medicine (2014)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2010)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

I have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.

CLINICAL TRIALS

- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia, Recruiting
- Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies, Recruiting
- Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma, Recruiting
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas, Not Recruiting
- A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO), Not Recruiting
- A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6, Not Recruiting
- Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma, Not Recruiting
- Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma, Not Recruiting
- Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting
- Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy., Not Recruiting
- Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006), Not Recruiting
- Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma, Not Recruiting
- Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087), Not Recruiting

Publications

PUBLICATIONS

- **Long-term survival in AIDS-related primary central nervous system lymphoma.** *Neuro-oncology*
Gupta, N. K., Nolan, A. n., Omuro, A. n., Reid, E. G., Wang, C. C., Mannis, G. n., Jaglal, M. n., Chavez, J. C., Rubinstein, P. G., Griffin, A. n., Abrams, D. I., Hwang, J. n., Kaplan, et al
2016
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
- **Role of FNA with core biopsy or cell block in patients with nodular lymphocyte-predominant Hodgkin lymphoma.** *Cancer cytopathology*
Gupta, S. n., Long, S. R., Natkunam, Y. n., Kong, C. S., Gupta, N. K., Gratzinger, D. n.
2020
- **Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply** *JOURNAL OF CLINICAL ONCOLOGY*

- Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019; 37 (9): 755-+
- **Reply to J. Wang et al.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019: JCO1801907
 - **AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Reid, E., Suneja, G., Ambinder, R. F., Ard, K., Baiocchi, R., Barta, S. K., Carchman, E., Cohen, A., Crysler, O. V., Gupta, N., Gustafson, C., Hall, A., Johung, et al
2019; 17 (2): 171-89
 - **AIDS-Related Kaposi Sarcoma, Version 2.2019** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Reid, E., Suneja, G., Ambinder, R. F., Ard, K., Baiocchi, R., Barta, S. K., Carchman, E., Cohen, A., Crysler, O. V., Gupta, N., Gustafson, C., Hall, A., Johung, et al
2019; 17 (2): 171-89
 - **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. M., Esfahani, M., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018; 36 (28): 2845-+
 - **Circulating tumor DNA (ctDNA) in B-cell lymphoma**
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Green, M. R., Liu, C. L., Zhou, L., Glover, et al
WILEY.2018: 16-17
 - **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018: JCO2018785246
 - **Cancer in People Living With HIV, Version 1.2018 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Reid, E., Suneja, G., Ambinder, R. F., Ard, K., Baiocchi, R., Barta, S. K., Carchman, E., Cohen, A., Gupta, N., Johung, K. L., Klopp, A., LaCasce, A. S., Lin, et al
2018; 16 (8): 986-1017
 - **Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma** *58th Annual Meeting and Exposition of the American-Society-of-Hematology*
Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., Lovejoy, A. F., Chabon, J. J., Liu, C. L., Zhou, L., Glover, C., Visser, B. C., Poultsides, et al
AMER SOC HEMATOLOGY.2016
 - **Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma**
Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., Chabon, J. J., Esfahani, M., Liu, C., Zhou, L., Glover, C., Visser, B. C., Poultsides, et al
AMER SOC HEMATOLOGY.2016
 - **Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations**
Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C., Zhou, L., Glover, C., Advani, R. H., Maeda, L. S., Gupta, N. K., Levy, R., Kunder, et al
AMER SOC HEMATOLOGY.2016
 - **Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA** *SCIENCE TRANSLATIONAL MEDICINE*
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., Zhou, L., Glover, C., Visser, et al
2016; 8 (364)
 - **Noninvasive molecular subtyping and risk stratification of DLBCL.**
Scherer, F., Kurtz, D., Newman, A. M., Stehr, H., Craig, A. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C., Zhou, L., Glover, C., Advani, et al

AMER SOC CLINICAL ONCOLOGY.2016

- **The Transfusion Tether: Bridging the Gap Between End-Stage Hematologic Malignancies and Optimal End-of-Life Care.** *American journal of hematology*
Mannis, G. N., McNey, L. M., Gupta, N. K., Gross, D. M.
2016
- **Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium** *LEUKEMIA & LYMPHOMA*
Noy, A., Lensing, S. Y., Moore, P. C., Gupta, N., Aboulafia, D., Ambinder, R., Baiocchi, R., Dezube, B. J., Henry, D., Kaplan, L., Levine, A. M., Mitsuyasu, R., Ratner, et al
2016; 57 (7): 1731–34
- **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al
AMER SOC HEMATOLOGY.2015
- **Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis** *BONE MARROW TRANSPLANTATION*
Mannis, G. N., Logan, A. C., Leavitt, A. D., Yanada, M., Hwang, J., Olin, R. L., Damon, L. E., Andreadis, C., Ai, W. Z., Gaensler, K. M., Greene, C. C., Gupta, N. K., Kaplan, et al
2015; 50 (1): 40-44
- **New Meets Old: A Case Study and Review of Novel Therapeutics for the Treatment of CLL in Older Patients** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Gupta, N. K., Andreadis, C.
2014; 12 (10): 1371-1375
- **Diffuse Large B-cell Lymphoma** *Cancers in People with HIV and AIDS*
Gupta, N. K., Kaplan, L. D.
Springer.2014: 175–182
- **How I treat CNS lymphomas** *BLOOD*
Rubenstein, J. L., Gupta, N. K., Mannis, G. N., LaMarre, A. K., Treseler, P.
2013; 122 (14): 2318-2330
- **Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium** *LEUKEMIA & LYMPHOMA*
Bayraktar, U. D., Ramos, J. C., Petrich, A., Gupta, N., Lensing, S., Moore, P. C., Reid, E. G., Aboulafia, D. M., Ratner, L., Mitsuyasu, R., Cooley, T., Henry, D. H., Barr, et al
2012; 53 (12): 2383-2389
- **Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma** *LEUKEMIA & LYMPHOMA*
Gupta, N. K., Barker, J. N., Young, J. W., Noy, A.
2009; 50 (12): 2075-2077
- **Differential effects of neurotoxic destruction of descending noradrenergic pathways on acute and persistent nociceptive processing** *PAIN*
Martin, W. J., Gupta, N. K., Loo, C. M., Rohde, D. S., Basbaum, A. I.
1999; 80 (1-2): 57-65